Agios Pharmaceuticals, Inc.
AGIONASDAQHealthcare● Active
$27.44
$-0.85(-3.00%)
Market Cap$1.6B
P/E Ratio—
52W High$46
52W Low$22.24
Agios Pharmaceuticals, Inc. (AGIO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AGIO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $54.03M | $36.50M | $26.82M | $14.24M | $0.00M |
| Cost of Revenue | $11.52M | $4.17M | $9.50M | $1.70M | $18.78M |
| Gross Profit | $42.51M | $32.33M | $17.32M | $12.54M | ($18.78M) |
| Gross Margin %(computed) | 78.67% | 88.59% | 64.57% | 88.03% | — |
| Operating Expenses | |||||
| R&D Expenses | $334.36M | $301.29M | $288.90M | $279.91M | $256.97M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $514.64M | $458.07M | $408.81M | $401.58M | $359.64M |
| Operating Income | ($472.13M) | ($425.74M) | ($391.49M) | ($389.05M) | ($378.42M) |
| Operating Margin %(computed) | -873.87% | — | — | — | — |
| Interest Income | $56.38M | $48.08M | $33.34M | $12.79M | $0.84M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($413.80M) | $717.97M | ($352.09M) | ($231.80M) | ($356.51M) |
| Income Tax Expense | ($1.02M) | $44.24M | $0.00M | $0.00M | $0.00M |
| Net Income | ($412.78M) | $673.73M | ($352.09M) | ($231.80M) | $1604.71M |
| Net Margin %(computed) | -764.01% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $-6.36 |
| Wtd Avg Shares | 57.97M | 56.81M | 55.65M | 54.79M | 60.45M |
| EBITDA | ($466.95M) | ($420.08M) | ($384.86M) | ($380.48M) | ($337.73M) |
| EBITDA Margin %(computed) | -864.28% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Agios Pharmaceuticals, Inc. data
About Agios Pharmaceuticals, Inc. (AGIO) Income Statement
Agios Pharmaceuticals, Inc. (AGIO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AGIO reported revenue of $0.05B, gross profit of $0.04B (gross margin 78.67%), and net income of ($0.41B) — a net profit margin of -764.01%.
Frequently asked questions
AGIO · 4 questionsAgios Pharmaceuticals, Inc. (AGIO) reported revenue of $0.05B for 2025, up 48.0% year-over-year.
AGIO revenueAGIO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08